TOKYO -- Japan's Fujifilm Holdings will restart a clinical trial for its flu-fighting drug Avigan to treat Japanese COVID-19 patients as early as April, Nikkei has learned, giving new life to the medication that had been seen as a potential game changer in the early stages of the pandemic.
Avigan, which has already been approved in India and Indonesia for emergency use to treat COVID-19 patients, could not win the green light in Japan last year after a health ministry expert board postponed a decision in December.
